1-methyl-1,2,3,4-tetrahydroisoquinoline has been researched along with Parkinsonian Disorders in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Chiba, T; Ishikawa, R; Kambe, T; Munakata, H; Saitoh, T; Taguchi, K | 1 |
| Antkiewicz-Michaluk, L; Michaluk, J; Nalepa, I; Romańska, I; Wąsik, A; Zelek-Molik, A | 1 |
| Antkiewicz-Michaluk, L; Romańska, I; Wąsik, A | 1 |
| Antkiewicz-Michaluk, L; Michaluk, J; Polak, D; Romańska, I; Wąsik, A | 1 |
| Kotake, Y; Ohta, S; Okuda, K | 2 |
| Fujitani, M; Kotake, Y; Makino, Y; Ohta, S; Shintani, H; Yamakawa, T | 1 |
| Abe, K; Miyatake, T; Ren, J; Sano, T; Shinohara, T; Taguchi, K; Utsunomiya, I; Wasai, T | 1 |
| Abe, K; Ishiwata, K; Kawamura, K; Koyanagi, Y; Saitoh, T; Sano, T; Senda, M; Taguchi, K; Toda, J | 1 |
9 other study(ies) available for 1-methyl-1,2,3,4-tetrahydroisoquinoline and Parkinsonian Disorders
| Article | Year |
|---|---|
Preventative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives (
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroprotective Agents; Parkinsonian Disorders; Tetrahydroisoquinolines | 2022 |
Neuroprotective Effect of the Endogenous Amine 1MeTIQ in an Animal Model of Parkinson's Disease.
Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Hyperkinesis; Male; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Tetrahydroisoquinolines | 2016 |
Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Male; Microdialysis; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Tetrahydroisoquinolines; Time Factors | 2016 |
The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Tetrahydroisoquinolines | 2016 |
Determination method of 1-methyl-1,2,3, 4-tetrahydroisoquinoline, an endogenous parkinsonism-preventing substance, by radioimmunoassay.
Topics: Animals; Antibody Formation; Blotting, Western; Brain Chemistry; Dopamine Antagonists; Female; Haptens; Immune Sera; Isoquinolines; Male; Parkinsonian Disorders; Rabbits; Radioimmunoassay; Rats; Rats, Wistar; Sensitivity and Specificity; Serum Albumin, Bovine; Tetrahydroisoquinolines; Time Factors | 2002 |
Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Dopamine; Dopamine Antagonists; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Tetrahydroisoquinolines | 2006 |
Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain.
Topics: Animals; Brain; Isoquinolines; Macaca fascicularis; Parkinsonian Disorders; Tetrahydroisoquinolines; Tissue Distribution | 1999 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypokinesia; Immunohistochemistry; Isoquinolines; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Serotonin; Stereoisomerism; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 2001 |
Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Hypokinesia; Isoquinolines; Ligands; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Parkinsonian Disorders; Radioligand Assay; Receptors, Dopamine D2; Stereoisomerism; Substantia Nigra; Synapses; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase; Up-Regulation | 2001 |